Chronic hepatitis C trial initiated in Mexico using Interferon Sciences' natural-source alpha interferon.NEW BRUNSWICK, N.J.--(HealthWire)--July 8, 1996--Interferon Sciences Inc. (ISI ISI International Sensitivity Index, see there ) (Nasdaq:IFSC IFSC Irish Financial Services Centre IFSC International Federation of Surgical Colleges (Switzerland) IFSC Indian Financial System Code IFSC International Fuzzy Systems Conference IFSC Information Field Size Integrated Circuit Card ) announced today that its licensee, Industria Farmaceutica Andromaco (Andromaco), has commenced a clinical trial in Mexico utilizing ISI's injectable formulation of Interferon Alfa-n3, the Company's highly purified, multispecies, natural-source alpha interferon, for the treatment of patients infected with chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis C virus. This study is sponsored by Andromaco under both U.S. and Mexican Investigational New Drug (IND) applications, and is being conducted at the National Institute of Nutrition in Mexico City. Patients in this study are treated using a different treatment schedule and frequency from that used in previous trials conducted by ISI on patients infected with chronic hepatitis C virus. The results of this trial will provide information to help evaluate the safety and efficacy of this altered treatment regimen. In February 1994, ISI entered into a distribution agreement with Andromaco in Mexico for its Interferon Alfa-n3 injectable product. Andromaco, a privately-held pharmaceutical company which specializes in oncology and immunology products, has obtained approval from Mexican regulatory authorities to sell this product in Mexico for the treatment of genital warts genital warts: see human papillomavirus. , and is marketing the product under the trade name ALTEMOL(R). Interferon Sciences Inc. is a biopharmaceutical company engaged in the study, manufacture and sale of pharmaceutical products based on its highly purified, multispecies, natural-source alpha interferon. The Company's ALFERON(R) N Injection product has been approved by the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. for the treatment of certain types of genital warts, and is being studied for the potential treatment of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. , hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. and other indications. The Company also has other natural-source alpha interferon formulations in various stages of development for the potential treatment of viral and immune system diseases and cancer. CONTACT: Interferon Sciences Inc., New Brunswick Lawrence M. Gordon, Chief Executive Officer, 908/249-3250, ext. 545 Stanley G. Schutzbank, Ph.D., President, 908/249-3250, ext. 502 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion